3D human liver tissue from pluripotent stem cells displays stable phenotype in vitro and supports compromised liver function in vivo by Rashidi, Hassan et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3D human liver tissue from pluripotent stem cells displays stable
phenotype in vitro and supports compromised liver function in
vivo
Citation for published version:
Rashidi, H, Luu, N-T, Alwahsh, SM, Ginai, M, Alhaque, S, Dong, H, Tomaz, RA, Vernay, B, Vigneswara, V,
Hallett, JM, Chandrashekran, A, Dhawan, A, Vallier, L, Bradley, M, Callanan, A, Forbes, SJ, Newsome, PN
& Hay, DC 2018, '3D human liver tissue from pluripotent stem cells displays stable phenotype in vitro and
supports compromised liver function in vivo', Archives of toxicology, vol. 92, no. 10, pp. 3117–3129.
https://doi.org/10.1007/s00204-018-2280-2
Digital Object Identifier (DOI):
10.1007/s00204-018-2280-2
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Archives of toxicology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Vol.:(0123456789) 
Archives of Toxicology 
https://doi.org/10.1007/s00204-018-2280-2
IN VITRO SYSTEMS
3D human liver tissue from pluripotent stem cells displays stable 
phenotype in vitro and supports compromised liver function in vivo
Hassan Rashidi1 · Nguyet‑Thin Luu2 · Salamah M. Alwahsh1 · Maaria Ginai4 · Sharmin Alhaque1 · Hua Dong5 · 
Rute A. Tomaz6 · Bertrand Vernay1 · Vasanthy Vigneswara2 · John M. Hallett1 · Anil Chandrashekran7 · Anil Dhawan7 · 
Ludovic Vallier6 · Mark Bradley5 · Anthony Callanan4 · Stuart J. Forbes1 · Philip N. Newsome2,3 · David C. Hay1 
Received: 23 June 2018 / Accepted: 31 July 2018 
© The Author(s) 2018
Abstract
Liver disease is an escalating global health issue. While liver transplantation is an effective mode of therapy, patient mor-
tality has increased due to the shortage of donor organs. Developing renewable sources of human liver tissue is therefore 
attractive. Pluripotent stem cell-derived liver tissue represents a potential alternative to cadaver derived hepatocytes and 
whole organ transplant. At present, two-dimensional differentiation procedures deliver tissue lacking certain functions and 
long-term stability. Efforts to overcome these limiting factors have led to the building of three-dimensional (3D) cellular 
aggregates. Although enabling for the field, their widespread application is limited due to their reliance on variable biologi-
cal components. Our studies focused on the development of 3D liver tissue under defined conditions. In vitro generated 3D 
tissues exhibited stable phenotype for over 1 year in culture, providing an attractive resource for long-term in vitro studies. 
Moreover, 3D derived tissue provided critical liver support in two animal models, including immunocompetent recipients. 
Therefore, we believe that our study provides stable human tissue to better model liver biology ‘in the dish’, and in the future 
may permit the support of compromised liver function in humans.
Keywords Liver tissue · Pluripotent stem cell · Stable cell phenotype · Implantable liver graft · Interdisciplinary research
Introduction
The liver performs a wide range of functions essential for 
body function. Significant loss of liver function therefore 
has serious consequences for human health (Ebrahimkhani 
et al. 2014). In the UK, liver disease is the fifth biggest 
killer, and unlike the top four, the incidence is increasing. 
Orthotopic liver transplantation (OLT) is the most effective 
treatment for acute or end-stage liver failure. However, due 
to the shortage of organ donors, and complications associ-
ated with lifelong immunosuppression, there is an impetus 
to develop alternative therapies.
While donor hepatocytes have been used to success-
fully treat metabolic liver disease (Alwahsh et al. 2018), 
the graft is eventually lost. This is further compounded by 
the scarcity of human hepatocytes. Therefore, we and oth-
ers have proposed that pluripotent stem cells (PSCs) are a 
credible alternative with which to generate a stable source 
of quality assured human liver tissue for applied medicine. 
PSCs can self-renew and differentiate to all cells types in 
the body, promising an unlimited supply of human tissue for 
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application. To this end, several protocols have been devel-
oped to efficiently generate hepatocyte-like cells (HLCs), 
mainly employing two-dimensional differentiation systems 
(Hay et al. 2007, 2008a, b; Agarwal et al. 2008; Sullivan 
et al. 2010; Hannan et al. 2013; Loh et al. 2014). Despite 
recent improvements (Takayama et al. 2013; Cameron et al. 
2015; Wang et al. 2017), 2D-derived HLCs exhibit foetal 
features and unstable phenotype in vitro, limiting their clini-
cal application.
To improve hepatocyte stability, three-dimensional (3D) 
approaches have been explored to generate human liver tis-
sue (Szkolnicka and Hay 2016). Those processes employ 
matrix or scaffold-driven formation of 3D aggregates with 
or without inclusion of other cell types (Gieseck et al. 2014; 
Takebe et al. 2014; Camp et al. 2017). These models have 
been important to further our understanding of human devel-
opment and physiology. However, they were manufactured 
using components which suffer from batch variation and this 
limits widespread application of the technology.
In these studies, we addressed these issues describing a 
scalable and defined differentiation process to generate 3D 
human liver tissue. Notably, stem cell derived liver tissue 
displayed modest liver function for more than 365 days in 
culture. During differentiation, cell organisation became evi-
dent, correlating with stable function, reduced proliferation 
and loss of foetal protein secretion. Stem cell derived liver 
tissue was also transplanted in vivo providing critical liver 
support in immune-competent or deficient recipients with 
compromised liver function.
In conclusion, our study demonstrates that functional 
human liver tissue, derived from pluripotent stem cells, can 
be stably cultured in vitro for long periods of time and pro-
vide liver support in vivo. We believe this resource provides 
promise for in vitro applications, such as repeated dosing 
and disease modelling, and in the future may serve as a 
source of tissue for the clinic.
Experimental procedures
Maintenance of human PSCs
hPSC lines, including two embryonic stem cell lines (H9, 
Man12) and iPSC lines (FSPS13B and P106) were cultured 
on laminin 521 (BioLamina) coated plates in serum-free 
 mTeSRTM1 medium (STEMCELL Technologies) as previ-
ously described (Cameron et al. 2015). The cell lines were 
monitored regularly for mycoplasma infection and were 
propagated in antibiotic free medium.
Formation of self‑aggregated PSCs spheroids
Agarose microplates were manufactured in 256-well format 
using the3D Petri  Dish® mould (Sigma Aldrich) following 
the manufacturer instructions and transferred to 12-well 
plates (Corning). hPSCs scaled up on laminin-coated plas-
ticware, were incubated with 1 ml of Gentle Dissociation 
Buffer (STEMCELL Technologies) for 7–10 min at 37 C. 
Following this, single cell suspensions were prepared by 
pipetting the buffer up and down gently. The cell suspen-
sion was centrifuged at 0.2 rcf for 5 min and resuspended in 
mTeSR1 supplemented with 10 µM Y-27,632 (Calbiochem) 
at a density of 2.0 × 106 live cells/ml. The agarose micro-
plates were seeded by transferring 190 µl of cell suspen-
sion. After 2–3 h, 1 ml mTeSR1 supplemented with 10 µM 
Y-27,632 was gently added to each well of 12-well plate and 
incubated overnight.
Hepatic induction of self‑aggregated PSCs 
spheroids
Differentiation was initiated replacing  mTeSRTM1 with 
endoderm differentiation medium: RPMI 1640 containing 
1 × B27 (Life Technologies), 100 ng/mL Activin A (Pepro-
Tech), and 50 ng/mLWnt3a (R&D Systems). The medium 
was changed every 24 h for 72 h. On day 4, endoderm dif-
ferentiation medium was replaced with hepatoblast differen-
tiation medium, and this was renewed every second day for 
a further 5 days. The medium consisted of knockout (KO)-
DMEM (Life Technologies), knockout serum replacement 
(KOSR - Life Technologies), 0.5% Glutamax (Life Tech-
nologies), 1% non-essential amino acids (Life Technolo-
gies), 0.2% b-mercaptoethanol (Life Technologies), and 1% 
DMSO (Sigma). On day 9, differentiating cells were cul-
tured in the hepatocyte maturation medium HepatoZYME 
(Life Technologies) containing 1% Glutamax (Life Tech-
nologies), supplemented with 10 ng/ml hepatocyte growth 
factor (HGF; PeproTech) and 20 ng/ml oncostatin m (Pepro-
Tech) as described previously (Cameron et al. 2015; Wang 
et al. 2017). On day 21, cells were cultured in maintenance 
medium consisted of William’s E media (Life Technologies), 
supplemented with 10 ng/ml EGF (R&D Systems), 10 ng/ml 
VEGF (R&D Systems), 10 ng/ml HGF (PeproTech), 10 ng/
ml bFGF (PeproTech), 10% KOSR, 1% Glutamax, and 1% 
penicillin–streptomycin (Thermo Fisher Scientific) for the 
rest of study.
Histology and immunofluorescence
3D spheroids were fixed in ice-cold methanol for 30 min., 
washed in PBS, and embedded in agarose. Agarose-embed-
ded spheroids were embedded in paraffin and 4 µm sections 
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were obtained. Antigen retrieval was performed by heating 
dewaxed and rehydrated sections in 1 × Tris–EDTA buffer 
solution for 15 min in microwave. Washed slides were used 
for subsequent staining.
Paraffin-embedded 4-µm liver sections were stained 
with Eosin and Hematoxylin and mounted in Pertex before 
microscopy. To assess glycogen storage, sections were 
stained by periodic acid-Schiff (PAS, Sigma) following the 
manufacturer’s instructions. Brightfield images were taken 
using a Nikon Eclipse e600 microscope equipped with a 
Retiga 2000R camera (Q-Imaging) and Image-Pro Premier 
software.
To stain sectioned spheroids, stem cell derived tissue was 
blocked with 10% BSA in PBS-tween (PBST) and incubated 
with primary antibody overnight at 4 °C, and detected using 
species-specific fluorescent-conjugated secondary antibody 
(Alexa Flour 488/Alexa Flour 568; Invitrogen). Sections 
were counterstained with DAPI (4′,6-diamidino-2-phenylin-
dole) and mounted with Fluoromount-G (SouthernBiotech) 
before microscopy.
An extended staining protocol was developed and opti-
mised to stain whole mount 3D Heps. Briefly, MeOH fixed 
spheroids were washed and rehydrated in PBS. Following 
overnight blocking in 10% BSA in PBST, the spheroids were 
incubated with primary antibody at desired concentration 
(Supplementary Table 1) with gentle agitation at 4 °C over-
night followed by 8 washes with 0.1% PBST (each wash 1 h) 
under gentle agitation at room temperature (RT). Secondary 
antibodies were incubated at 4 °C overnight and washed 
as described above (Supplementary Table 2). The nucleus 
was counterstained with Draq5 (Life Technologies) before 
images were acquired on a confocal microscope (Leica SP5).
qRT‑PCR
RNA was extracted from 3D Heps using an RNeasy Mini 
RNA Extraction kit (Qiagen). RNA quantity and quality 
were assessed using a Nanodrop system. Following this, 
cDNA was amplified using the  RT2 First Strand Kit (Qia-
gen) following the manufacturer’s instruction. qPCR was 
performed with TaqMan Fast Advance Mastermix and 
primer pairs listed in Supplementary Table 3 and analysed 
using a Roche LightCycler 480 real-time PCR system. Gene 
expression was normalised to glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and expressed as relative expres-
sion over 3D aggregate on day 0 of differentiation as control 
sample. qPCR was performed in triplicate and data analysis 
was performed using Roche LightCycler 480 software (ver-
sion 1.5).
Hepatocyte phenotyping
To measure Cyp3A activity, 50 µM of Luciferin-PFBE sub-
strate (Promega) was incubated with cells in HepatoZYME 
medium supplemented with 10 ng/ml HGF. Cytochrome 
P450 activity was measured 24 h later using the P450-Glo 
assay kit (Promega) according to manufacturer’s instruction. 
To measure AFP and ALB secretion, the culture medium 
was collected after 24 h and quantified using commercial 
available ELISA kits (Alpha Diagnostics International). 
Data were normalised with the total protein content meas-
ured using bicinchonic acid (BCA) assay (Thermo Fisher 
Scientific).
For the intraperitoneal transplant study, human ALB level 
was measured by ELISA (MULTI-SPOT® 96 4-Spot Cus-
tom Human ALB Singleplex, Maryland, USA), in serum 
collected from 50% PHx after 4 weeks post vehicle or 2 × 106 
hepatospheres transplantation. Stored serum samples were 
thawed at room temperature and tested for ALB concentra-
tion which is quoted as pg/mL.
Scaffold production
Non-woven Polycaprolactone (PCL; Sigma Aldrich, UK) 
scaffolds were produced using the EC-DIG electrospinning 
platform (IME Technologies, Netherlands). Low concen-
tration (8% wt/v) and high concentration (14% wt/v) PCL 
solutions were generated by dissolving PCL pellets on a 
rolling mixer overnight in Hexafluoroisopropanol (HFIP; 
Manchester Organics, UK) or Chloroform/ethanol (5:1) 
(Sigma Aldrich, UK), respectively. The solutions were then 
used to generate electrospun scaffolds with small and large 
fibre diameters. To fabricate small fibre with diameter of 
1.38 µm ± 0.16 µm, electrospinning experiments were car-
ried out with low concentration (8% wt/v) PCL solution and 
a 26G needle. The feeding rate of the solution was 2.0 mL/h. 
The voltage was between 14 and 16 kV. And the distance 
between the needle tip and the collecting substrate was 
15 cm with mandrel speed of 250 rpm. To generate large 
fibre with diameter of 6.68 µm ± 1.18 µm, high concentra-
tion (14% wt/v) PCL solutions was fed at 7.0 ml/h. The dis-
tance between the needle tip and the collecting substrate 
was 18 cm and the voltage was 20 kv. The size of needle and 
mandrel speed was similar to small fibre.
To fabricate hexagonal electrospun scaffolds, polycap-
rolactone (Scientific Polymer, US, Mw = 100,000) was dis-
solved in a mixed solvent of DMF and THF (1/1, w/w) with 
a final polymer concentration of 14% (w/w). Electrospinning 
experiments were carried out on a typical electrospinning 
setup (Spraybase, Ireland), with a 22G needle. The feeding 
rate of the solution was 0.3 mL/h. The voltage was between 
6 and 8 kV. And the distance between the needle tip and 
the collecting substrate was 7 cm. Room temperature was 
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controlled at 20 °C, and the relative humidity was around 
40%.
Scanning electron microscopy
Scanning electron microscopy (SEM) (Hitachi S-4700; 
Hitachi, Japan) was used to image the electrospun mats. 
Samples were sputter coated with gold/palladium using the 
E5200 automatic sputter coater (Polaron; Quorum Technolo-
gies, UK).
Intraperitoneal transplantation
Both male (30–36  g) and female (23–27  g) C57BL6/J, 
 Rag2−/−IL2rg−/− mice that lack lymphocytes (B and T) and 
natural killer cells were used. Animals were housed in a spe-
cific pathogen-free environment and kept under standard con-
ditions with a 14 h day/10 h night cycle and had a free access 
to food and water. All animal experiments were performed 
under procedural guidelines, severity protocols, and with 
ethical permission from the University of Edinburgh Animal 
Welfare and Ethical Review Body and the UK Home Office.
Liver injury was induced in immunocompromised 
 (Rag2−/−IL2rg−/−) mice by commonly used Three Knots 
methods for partial hepatectomy (PHx). 50% PHx, the left lobe 
and the left part of the median lobe were excised. Gallblad-
der was preserved in this surgical procedure. Mice received 
200 µL HepatoZYME (vehicle) or 2 × 106 hepatospheres that 
were loaded intraperitoneally. The abdominal incision was 
closed and animals were monitored closely until recovery 
from anaesthesia. Body weights of the rodents were measured 
10 days before starting the experiment and every day after 
transplantation. Four weeks after human cell transplantation, 
the recipient mice were euthanized according to UK Home 
Office regulations. Blood was collected by cardiac puncture and 
centrifuged to collect serum. Livers were harvested and fixed 
in 4% buffered-formaldehyde for 24 h and were then stored 
in paraffin. Animals reaching experimental severity protocol 
boundaries were excluded from analysis; otherwise, all animals 
were included. Control group (no surgery, n = 5) was used to 
determine the baseline of liver function and injury tests.
Subcutaneous transplantation
Immune-deficient, fumarylacetate hydrolase  (Fah−/−), 
 Rag2−/− and  Il2rg−/− animals on the NOD-strain back-
ground (FRGN) were originally obtained from Yecuris. The 
immune-normal,  Rag2+/+/Il2rg+/+, with Fah knockout mice 
(FAH) have been generated and maintained by the New-
some group at Birmingham. Animals were maintained and 
housed under conventional conditions in the Biomedical 
Service Unit at the University of Birmingham. They were 
at constant temperature and humidity in a 12-h controlled 
light–dark cycle and were used in accordance with Home 
Office guideline. Surgery was performed efficiently and 
strictly according to approved protocol for induction of liver 
injury under project licence (P3CDEF650), with maximal 
care to minimize suffering. They regained consciousness 
within 5–10 min after surgery and given pain-relief incor-
porated in the soft food for maximal comfort.
Animals were aged 8–12 weeks at the start of the experi-
ments. Following isoflurane anaesthesia a small incision 
(~ 1 cm) was made on the left lower back of the animal. 
The scaffold (10 mm in size) was carefully placed onto the 
body tissue facing downwards. After suture the animals were 
allowed to recover and kept on the medication: NTBC to 
prevent liver damage for a further 3 days to allow the implant 
to settle. Following this NTBC support was replaced with 
normal drinking water which would induce liver injury due 
to the accumulation of toxic metabolites. Animal wellbeing 
was monitored every other day for further 14 days.
Histopathological sections
Samples were fixed for at least 24 h in 10% neutral buffered 
formalin solution (pH7.4) at room temperature (RT). Tissue 
was embedded in paraffin and sectioned at 4 µm. Prior to 
staining, sections were dewaxed in xylene and rehydrated 
using graded industrial denatured alcohol (IDA). Tissue sec-
tions were stained with standard histological Harris’s Hae-
matoxylin and Eosin (H&E) (Leica, German). All sections 
were rehydrated in graded IDA, cleared in xylene and were 
mounted with DPX (leica Biosystems,UK); cover slipped 
and images were captured with Zeiss Axio ScanZ1.
Serum level of liver damage biomarkers and Human 
albumin ELISA
Blood samples were withdrawn by cardiac puncture dur-
ing isofluorane anesthesia and allowed to clot at room tem-
perature for at least 30 min. After centrifugation serum was 
collected and stored at − 80 °C until use. The mouse liver 
biomarkers: ALT, AST, bilirubin, and ALB, were measured 
at the Clinical Biochemistry Laboratory of the Women’s 
Hospital Birmingham (Birmingham, UK). Human ALB 
in the mouse serum samples was measured using a Human 
Albumin ELISA Quantitation Kit (Abcam,UK) according to 
the manufacturer’s instructions.
Statistics
Data were analysed by GraphPad Prism (version 7). Stu-
dent’s t test or Mann–Whitney tests were used to determine 
the difference, which was set at P < 0.05. We did not use 
statistical methods to predetermine sample size, there was no 
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randomization designed in the experiments, and the studies 
were not blinded. Number of animals = 3–20 per group from 
12 independent experiments, significance was determined by 
One-way analysis of ANOVA Bonferroni, Mann Whitney 
test or by Tukey post hoc, as suitable. Data are represented 
as mean ± SEM or median where appropriated, *p < 0.05, 
**p < 0.01, ***p < 0.001. ****p < 0.0001; *comparison of 
SC-HLC verse SC + HLC during NTBC withdraw. + is the 
comparison of control NTBC to the SC-HLC-NTBC group.
Results
Building stable and defined 3D human liver tissue 
in vitro
Aggregated human embryonic stem cells (hESCs) and 
induced pluripotent stem cells (hiPSCs) were differentiated 
toward the hepatocyte lineage in suspension or agarose mul-
tiwell plates using a defined procedure (Fig. 1a and Supple-
mentary Fig. 1). To produce homogenous three-dimensional 
spheres (3D Heps) of defined size, the agarose multi-well 
plate technology was routinely employed (Supplementary 
Fig. 1  Generation of scalable, defined and stable  3D hepatospheres 
from hPSCs. a A stepwise defined protocol for the generation of 
3D Heps. b Brightfield image of 3D Heps at day 365 of differentia-
tion. Scale bar, 50 µm. c H&E staining of 3D spheres at various time 
points. A central mesenchymal core (MC) was surrounded by several 
layers of hepatocytes (hep). Scale bar, 50 µm. d Expression of vimen-
tin (VIM) was detected in cells located in MC. Nuclei were stained 
with DAPI. Scale bar, 50 µm
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Fig. 1). During cellular differentiation, 3D Heps exhibited 
typically hepatic morphology with distinctive cell borders 
which was maintained until termination of cell culture at 
d365 (Fig. 1b). Haematoxylin and Eosin staining indicated 
that the outer layer was 2–3 cells in depth with a dense core 
that was expelled in most spheroids between days 8 and 10 
to form cystic 3D Heps which could be harvested (Day 8a; 
Fig. 1c). By day 20, structural reorganisation was observed 
(Fig. 1c), a process that continued until day 45, when two 
distinct compartments were observed. The outer layer 
was composed of hepatocyte-like cells with mesenchymal 
vimentin positive cells in the core (Fig. 1d). At these stages 
of differentiation cell proliferation decreased (Supplemen-
tary Fig. 2a) and 3D Heps acquired the ability to store gly-
cogen (Supplementary Fig. 2b).
Tracking endoderm differentiation from PSCs
During cellular differentiation, we examined pluripotent 
and definitive endoderm gene expression from d0 to d8. 
During differentiation, 3D aggregates down-regulated the 
pluripotent transcripts, OCT4 and NANOG. SOX17 and 
FOXA2 levels increased as the cells differentiated toward 
definitive endoderm (Fig. 2a). These data were confirmed 
Fig. 2  Evaluation of pluripotent and definitive endoderm markers. a 
Downregulation of OCT4 and NANOG expression by d8 which was 
accompanied by upregulation of SOX17 and FOXA2 as markers of 
definite endoderm by d3 of differentiation. b Expression of Oct4 and 
Nanog was reduced during differentiation. In contrast, the expres-
sion of Sox17 and FoxA2 increased during differentiation. n = 3 per 
group, significance was determined One-way ANOVA Tukey post 
hoc test. Data are represented as mean ± SEM, *p < 0.05, **p < 0.01, 
***p < 0.001. Nuclei were stained with DAPI. Scale bar is 50 µm
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Fig. 3  Evaluation of hepatic markers at gene and protein level. a 
Increased expression of HNF4A, AFP and ALB during cell differ-
entiation and compared to human liver (HL). b Confocal micros-
copy of 3D Heps for Hnf4A, ECad, ZO1 and Alb. c Expression of 
hepatic markers was limited to cells within the periphery. n = 3 per 
group, significance was determined by one-way ANOVA Tukey post 
hoc test. Data are represented as mean ± SEM, *p < 0.05, **p < 0.01, 
***p < 0.001. Nuclei were stained with DAPI. Scale bar is 50 µm
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by immunostaining of sectioned spheroids (Fig. 2b). Sphe-
roid commitment to the hepatic lineage was supported by 
increased transcript levels for hepatic nuclear factor 4 alpha 
(HNF4A), alpha fetoprotein (AFP) and albumin (ALB) 
(Fig. 3a). These data were further supported by whole mount 
immunostaining of 3D Heps. 3D Heps at d20 expressed the 
tight junction marker ZO1, the liver enriched transcription 
factor HNF4A, ALB and an epithelial marker, E-Cadherin 
(ECAD) (Fig. 3b). 3D Hep protein expression was examined 
40 days later demonstrating stable expression of HNF4A, 
ALB, ECAD and ZO1 (Fig. 3b). To examine 3D Hep struc-
ture, we performed sectioning followed by immunostain-
ing for ALB, HNF4A, AFP, ECAD, alpha 1 anti-trypsin 
(A1AT), PROX1 and ZO1 at two time points. Hepatic 
marker expression was limited to cells on the periphery 
and absent from the sphere’s core (Fig. 3c, Supplementary 
Fig. 3). Similarly, the expression of phase I and II proteins: 
Cyp3A4 (red) (Fig. 4a) and SULT1 (red) and SULT2 (green) 
(Fig. 4a) was restricted to the outer layer. A similar pattern 
was observed for the cell membrane transporters, multi-drug 
resistant protein 1 (MRP1, green), and ATP-binding cassette 
sub-family B member 11 (ABCB11, red) (Fig. 4b).
Fig. 4  Functional analysis of 3D Heps. a Expression of Phase 
I (Cyp3A4) and Phase II (SULT1 & SULT2) markers in 3D Heps. 
b Expression and localisation of drug transporters (MRP1 and 
ABCB11) in d45 3D Heps. c Cyp3A activity of differentiated 3D 
Heps maintained in HepatoZYME. d Long-term Cyp3A activity of 
differentiated 3D Heps maintained in maintenance medium. e 3D 
Heps remain drug inducible for 365 days in vitro. f Secretion of AFP 
and ALB in 3D Heps at days 20 and 90
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3D Heps are active for up to 1 year in vitro
Post-gene expression analysis, we determined the functional 
capacity of stem cell-derived liver tissue. To build a stable 
system, we developed a maintenance medium that supported 
long-term culture of 3D liver tissue in vitro. Our previous 
attempts for long-term culture using metabolic medium led 
to sphere disaggregation, reduced Cyp3A activity and cell 
death by d60 in vitro (Fig. 4c), whereas the 3D maintenance 
medium permitted the culture of 3D Heps for 365 days with 
respectable Cyp3A activity (Fig. 4d). Mature metabolic 
activity was corroborated by drug inducible Cyp3A activity 
(Fig. 4e) and by the loss of AFP secretion and maintenance 
of ALB secretion (Fig. 4f).
3D Heps can be generated from hESC and hiPSC 
lines using the same methodology
To determine the reproducibility of our protocol, parallel 
differentiation of two hESC (H9 & Man12) and two hiPSC 
(FSPS13B and P106) lines was performed. The efficiency 
of the process was examined by analysing protein secretion 
and metabolic activity at d20. 3D Heps were derived suc-
cessfully from all four tested lines with varying levels of 
function. Among tested lines, Man12 had secreted 3.4 µg 
of AFP per mg protein into the culture media in 24 h which 
was significantly higher than the other three lines (Supple-
mentary Fig. 4a). Similarly, Man12 secreted 800 ng ALB 
into the culture media which was the highest among tested 
lines (Supplementary Fig. 4b). Cyp1A2 activity was notably 
Fig. 5  Development and characterisation of a sub-cutaneous implant. 
a Fabrication of electrospun PCL scaffolds with four different geom-
etries. b 3D Heps remained metabolically functional 16  days post 
seeding on electrospun scaffolds with peak activity on large random 
fibre. c 3D Heps maintained expression of key markers including 
HNF4A and ALB following seeding on the large fibre scaffold. n = 3 
per group; significance was determined by one-way ANOVA Tukey 
post hoc test. Data are represented as mean ± SEM, *p < 0.05. Scale 
bar is 50 µm
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higher in iPSC 3D Heps compared to hESC-derived 3D 
Heps (Supplementary Fig. 4c). Similar levels of Cyp3A 
activity were detected in all 3D Heps, except for Man12 
which displayed lower levels (Supplementary Fig. 4d), con-
sistent with a previous study (Cameron et al. 2015).
3D Heps improve rodent recovery following partial 
hepatectomy
Stem cell-derived 3D Heps were transplanted intraperi-
toneally immediately following 50% partial hepatectomy 
(PHx) into C57BL6/J,  Rag2−/−IL2rg−/−mice. Mice which 
received vehicle control lost about 8–10% of their initial 
body weights and started to regain weight two weeks after 
surgery. In contrast, mice that received 3D Heps regained 
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weight within 4 days of surgery and recovered their initial 
body weight after 14 days (Fig. Supplementary 5a). These 
observations were supported by secretion of human albumin 
in 3D Hep recipient mice (Supplementary Fig. 5b) and a 
reduction in aspartate aminotranferase (AST), a marker of 
hepatocellular injury (Supplementary Fig. 5c). In both treat-
ment groups circulating bilirubin levels remained unaltered 
(Supplementary Fig. 5d) While these experiments provided 
proof of concept, we decided to take a less invasive approach 
to provide mammalian liver support, acknowledging that 
this would be the most likely treatment option for liver dis-
ease in patients not eligible for cell based therapy or a liver 
transplant.
Sub‑cutaneous implant of 3D Heps to support 
failing liver function in vivo
Working with materials chemists and engineers, we identi-
fied FDA approved materials suitable for human use. Elec-
trospun scaffolds were prepared from polycaprolactone 
(PCL) with four different geometries and one coated with 
polyacrylate (polymer 9G7). H9-derived 3D Heps were 
seeded on the PCL scaffold at d14 of differentiation and 
attached to the fibres (Fig. 5a). 16 days post replating, 3D 
Heps displayed Cyp3A P450 function (Fig. 5b) and main-
tained expression of Hnf4a and Alb (Fig. 5c). The fabrica-
tion of large PCL fibres was most reproducible and was used 
for the sub-cutaneous implant experiments.
Stem cell-loaded implants were deployed in 2 murine 
models of tyrosinemia. We successfully transplanted 
empty scaffolds and 3D Hep-loaded scaffolds into 
8- to 12-week-old mice, with wound healing occur-
ring without any infection. The scaffolds were well 
tolerated and vascularised (Fig.  6a). Three days after 
transplantation, (2-(2-nitro-4-trifluoromethylbenzyol)-
1,3cyclohexanedione (NTBC) was removed from the 
drinking water in the empty and 3D Hep-loaded scaf-
folds. Body weight recovery and liver biochemistry was 
then followed for 14 days. Of note, body weight reduced 
upon the withdrawal of NTBC in mice receiving acellu-
lar scaffolds (squares), while this effect was significantly 
reduced by the presence of 3D Heps in the scaffold (tri-
angles) between day 8 and day 14 (*p < 0.05, **p < 0.01, 
***p < 0.001. ****p < 0.0001) (Fig. 6b). Human albumin 
was detected in mouse serum with 3D Heps-loaded scaf-
folds (open and solid triangles) but not in the acellular 
scaffold groups (squares, and open circles), indicating 
that the human graft was functional and linked to host 
circulation (Fig. 6c). Next we studied blood biochemistry. 
NTBC withdrawal resulted in significant elevation of liver 
damage markers alanine aminotranferase (ALT), AST and 
bilirubin (Fig. 6d). This was reduced in the 3D Hep-trans-
planted group, except for AST in FAH mice and bilirubin 
in FRGN mice (Fig. 6d). Histological analysis of liver sec-
tions was performed from NTBC treated mice (Fig. 6e, 
left panel), scaffold only treated mice (Fig. 6e, middle 
panel) and 3D Hep loaded scaffolds (Fig. 6e, right panel). 
The most severe liver injury was detected in the scaffold 
only group. Murine livers in this group displayed swollen 
hepatocytes, apoptotic cells and multi-segmented nuclei 
(Fig. 6e, middle panel). In addition, there were signs of 
bile duct alternation. This pathological process was less 
obvious in the group receiving NTBC (Fig. 6e, left) panel) 
or 3D Hep-loaded scaffolds(Fig. 6e, right panel).
Discussion
Mortality associated with end-stage liver disease has 
increased dramatically over the last 20 years. This is com-
pounded by the shortage of donor organs to treat liver dis-
ease. Therefore, scalable tissue models and regenerative 
therapies are urgently sought. While cell transplantation or 
Fig. 6  Supportive effect of 3D Hep loaded scaffolds in murine mod-
els of tyrosinaemia. a Macroscopic images depicting vascularisation 
on the scaffold (SC, left) and H&E staining showing a slight inflam-
matory infiltrate and giant cells (GC) within the scaffold (middle), as 
part of the degradation process. Blood vessels (BV) start to appear as 
part of the vascularisation process (right, X400). b Percentage change 
in body weight. Conventional FAH knock-out are indicated with 
open symbols, whereas immunocompromised FAH mice (FRGN) 
are shown in solid symbols. Circles indicate mice that continued to 
receive 2-(2-nitro-4-trifluoromethylbenzyol)-1,3cyclohexanedione 
(NTBC) in both strains of mice. The body weight reduced signifi-
cantly upon the withdrawal of NTBC in mice receiving acellular scaf-
folds (squares), although this effect was ameliorated by the presence 
of HLC in the scaffold (triangles). One-way ANOVA demonstrated 
that there was a significant difference between transplantation of acel-
lular and cellular scaffolds on the weight of animals between day 8 
and day 14 (*p < 0.05, **p < 0.01, ***p < 0.001. ****p < 0.0001). c 
Detectable levels of human albumin were observed in mouse serum 
with cellular scaffold implantation (solid circles and triangles) but 
not in the absence of HLC (squares, and open circles); with *p < 0.05, 
**p < 0.01, indicating that implanted human hepatocytes were func-
tional. d Serum levels of markers of hepatocellular damage, ALT, 
AST, bilirubin and albumin were measured 14  days after implanta-
tion of scaffolds; all marker levels were significantly increased after 
NTBC was replaced with normal drinking water (squares). Open 
symbols are FAH while solid symbols are FRGN. Markers of liver 
injury were reduced by the implantation of scaffold with cells, 
in FAH and FRGN mice. Data were collected from 12 independ-
ent experiments with n = 3–14 per group. *p < 0.05, **p < 0.01, 
***p < 0.001. ****p < 0.0001 by un-paired Mann–Whitney test. e 
Representative images of liver histology are shown indicating liver 
injury with swollen hepatocytes, apoptotic cells and fat droplets (mid-
dle panel). This damage was partially rescued by implantation of the 
cell containing scaffolds (right panel), with fewer swollen cells and 
leakage between hepatocytes. This was more similar to control liver 
histology shown in the left panel
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bioartificial liver devices offer promise to treat failing liver 
function, the shortage of good primary human hepatocytes 
has seriously restricted both endeavours (Demetriou et al. 
2004; Francipane et al. 2011; Thompson et al. 2015; Dhawan 
2015; Forbes et al. 2015; Oldhafer et al. 2016). Therefore, 
the establishment of renewable PSC systems has generated 
much excitement in the field.
Despite significant progress in the field, in vitro derived 
hepatocyte-like cells generally display a mix of adult and 
foetal features (Szkolnicka and Hay 2016). To improve cell 
phenotype, recent research has focussed on 3D differentia-
tion. There have been a number of influential papers pub-
lished in the 3D liver tissue space. In 2013 Takebe et al. 
provided proof of concept that mixing primary and stem cell 
derived cell types led to the generation of liver buds which 
display improved function in vitro and provided liver sup-
port in vivo (Takebe et al. 2013). This was followed by Huch 
et al. demonstrating that it was possible to isolate, expand 
and differentiate human bipotent liver progenitors to model 
human disease (Huch et al. 2015). Later that year the excit-
ing studies by Stevens et al. demonstrated that human pri-
mary cell types could be used to build liver aggregates when 
embedded in a biodegradable hydrogel. Following transplant 
into mesenteric fat, those aggregates could respond to cues 
provided by the damaged liver, expanding more than 50-fold 
in vivo (Stevens 2017). Most recently, pioneering studies 
from Takebe et al. have shown that it is possible to generate 
liver buds entirely from human iPSCs and at scale promis-
ing a renewable source of human liver tissue (Takebe et al. 
2017).
These studies have opened up new experimental avenues 
for modelling human physiology, regenerative medicine, and 
gene therapy. While these studies are enabling, the technol-
ogy described relies on variable components and/or depends 
on primary human tissue as a source of somatic cells. We 
believe that this restricts the routine scale up and deployment 
of such resources. Additionally, the invasive nature of the 
surgical procedure to deliver to the cells in vivo, combined 
with testing in immune deficient mice, are limiting factors 
when translating this technology toward human medicine.
We believe that the construction of stable human tis-
sue under defined conditions, combined with the ability to 
deploy regenerative therapies in immune competent indi-
viduals are important considerations. Therefore, the goal of 
our studies was to develop a defined differentiation system 
that was stable in nature and provided liver support in vivo. 
Notably, 3D Heps demonstrated modest Cyp3A activity for 
over 1 year in culture providing an exciting opportunity to 
model human liver physiology and further improve stem 
cell derived liver tissue. Additionally, stem cell derived 
tissue provided liver support in vivo and was associated 
with improved body weight, blood biochemistry and liver 
histology.
In conclusion, our study demonstrates the importance of 
3D differentiation and heterotypic cell interactions to gener-
ate stable human liver tissue. Looking ahead, we believe that 
this study provides a solid foundation with which to build 
bona fide and renewable liver tissue for human translational 
medicine.
Fig. 6  (continued)
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